The Senate hosted its inaugural Artificial Intelligence (AI) Insight Forum this week, described by Senate Majority Leader Chuck Schumer (D-NY) as “a gathering unlike any seen before, to debate a topic ...
The FDA process for determining whether a combination product will be regulated as a drug or a device has never failed to provoke comment, and the agency’s final guidance seems to sustain that trend ...
AI has quickly moved from experimentation to expectation. Boards are asking where it fits in the business. Investors are asking what value it creates. Regulators are asking how it is being governed.
On April 25, 2024, the U.S. Department of Labor (the “DOL”) finalized a collection of regulatory changes in its ongoing quest to update the definition of a “fiduciary” under ERISA and Section 4975 of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results